7^th International Pharmacy and Pharmaceutical Conference

Pharmaceutical Research and Development

Investment on pharmaceutical research and development Despite the fact that they are projected to increase at a compound annual growth rate (CAGR) of 2.8% through 2022, stakeholders and experts have noticed a decline in the return on investment (ROI). Pharmaceutical firms are coming under more and more pressure to either increase the success rates of their R&D or lower the cost of failure, which a breakthrough would ordinarily pay. From the first hazardous dose through market approval, the pharma research and development process has an average success rate of 4.9%. However, experts are debating whether the number of FDA-approved pharmaceuticals in 2016 was lower than in 2015, which raises the possibility that drug approvals have already peaked and will continue to drop. with a dismal forecast for increasing pharmaceutical research and development success rates.

• Basic research
• Applied research
• Experimental development